PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
Using BluePrint to elucidate the molecular heterogeneity of triple negative breast cancers
PUBLICATION: SABCS 2020 AUTHORS: Virginia G. Kaklamani, Cathy Graham, Karen L. Tedesco, Abirami Sivapiragasam, Jennifer A. Crozier, Apurva N. Shah, Yuan Yuan, Josien Haan, Andrea Menicucci, Michelle L. Bolner, Shiyu Wang, Lorenza Mittempergher, Erin Yoder, William Audeh9, FLEX Investigators' Group Background: Triple negative breast cancers (TNBC) are more aggressive, have Read More
5-year outcomes in the NBRST trial: preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival
PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Pellicane, Jr., Paul Baron, Peter Beitsch, Laura Lee, Michael Rotkis, Angela Mislowsky, Carrie Dul, Charles Nash, BichlienNguyen, Mary Murray, Paul Richards, Mark Gittleman, Stephanie Akbari, ShiyuWang, Erin B Yoder, Andrea Menicucci, Lisa Blumencranz, William Audeh, NBRST Investigators Group Background: MammaPrint Read More
The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in older patients
PUBLICATION: SABCS 2020 AUTHORS: Iris Noordhoek, Esther Bastiaannet, Ersan Lujinovic, Laura Esserman, Jelle Wesseling, Astrid Scholten, Carolien Schroders, Sjoerd Elias, Nienke de Glas, Judith Kroep, Johanneke Portielje, Miranda Kleijn, Gerrit-Jan Liefers Introduction: Adjuvant therapy for hormone receptor positive (HR+) breast cancer (BC) is guided by clinicopathological risk factors, but Read More
Prediction of benefit from adjuvant pertuzumab by BluePrint RNA sequencing in the APHINITY trial
PUBLICATION: SABCS 2020 AUTHORS:Ian E Krop, Lorenza Mittempergher, Joseph N Paulson, Fabrice Andre, Herve Bonnefo, Sherene Lo, Sibylle Lo1bl, Richard D Gelber', Carmela Caballero, Debora Fumagall, RaJ1th Bhaskaran, Christa Dreezen, Rene Bernards', Laura J van 't Veer and Martine J P1ccart Background: APHINITY is a phase Ill study (NCT01358877), which Read More
MammaPrint Guides Treatment Decisions in Breast Cancer: Results of the IMPACt Trial
Publication: Soliman et al. BMC Cancer (2020) 20:81 Authors: Hatem Soliman, Varsha Shah, Gordan Srkalovic, Reshma Mahtani, Ellis Levine, Blanche Mavromatis, Jayanthi Srinivasiah, Mohamad Kassar, Robert Gabordi, Rubina Qamar, Sarah Untch, Heather M. Kling, Tina Treece and William Audeh Title: MammaPrint guides treatment decisions in breast Cancer: results of Read More
MammaPrint and BluePrint NGS Results are Robust and Accurate for Patients with Early Stage Breast Cancer
PUBLICATION: AMP 2020 AUTHORS: Douglas Kingma, Kasey Lawrence, Sahra Uygun, Camila Zanette, Helen Yang, Sammy Mee, Lorenza Mittempergher, Anke Witteveen, Leonie Delahaye, Bob Chan, Annuska Glas 1. Tennessee Oncology, Nashville, TN; 2. Agendia Inc, Irvine, CA; 3. Agendia NV, Amsterdam, The Netherlands Introduction: MammaPrint (MP) and BluePrint (BP) are Read More
ESMO 2020: UltraLow Data from the IKA Cohort
PUBLICATION: ESMO 2020 AUTHORS: Mark Opdam, Vincent van der Noort, Miranda Kleijn, Anuska Glas, Ingrid Mandjes, Dinja Kruger, Paul van Diest, Jan Vermorken, Harm van Tinteren, Sabine Linn Background: Adjuvant tamoxifen is widely used as endocrine treatment for oestrogen receptor positive (ER+) breast cancers (BC). Guidelines recommend the use of Read More
